Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Horizon scanning for novel therapeutics for the treatment of prostate cancer

(2010) D. Bianchini et al.   ANNALS OF ONCOLOGY

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

(2010) Daniel C. Danila et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting CYP17: established and novel approaches in prostate cancer

(2008) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY